Adverum Biotechnologies – Public Company Spotlight at Ophthalmology Innovation Summit @ AAO 2019

Public gene therapy company Adverum Biotechnologies’ Aaron Osborne, MBBS MRCOpth, discusses ADVM-022, an intravitreal gene therapy for VEGF-driven retinal diseases.

Aaron Osborne, MD, Chief Medical Officer speaks for Adverum Biotechnologies during the Public Company Spotlight at OIS@AAO 2019.

REGISTER for our next ophthalmology conference today.

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.